Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
← catalyst calendarNCT06767514 · readout ≤ 620 d
Sponsored by Summit Therapeutics (industry) · SMMT — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
780estimated
Sites
274
Countries
Belgium, Canada, China +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-27 | actual | When the study began enrolling |
| Primary completion | Apr 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Biological: Ivonescimab Injection
- Biological: Pembrolizumab Injection
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to approximately 36 months
Progression free survival (PFS)
measured Up to approximately 36 months
Permalink · SMMT's whole pipeline · Catalyst calendar · Every registered study · What changed